Seres Therapeutics, Inc. (MCRB) Social Stream



Seres Therapeutics, Inc. (MCRB): $6.10

0.08 (+1.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MCRB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

Featured Post From StockTwits About MCRB

$MCRB @edon5 looks like you have good knowledge about all of this....so, we have a completed, double blinded, placebo controlled phase 3 study with positive results (stastically significant), which by itself would likely be enough for fda approval...and then there's the additional open label phase 3 study searching for benefits of longer treatment with ser-109 and if there's a difference between those who already were treated once with it or not at all....am I getting it right? Also the sudden peak in SP last year was due to the results of the first ph3 result and after the drop we are nearly were it was prior to these ph3 results? Kind of an huge overreaction to a failed ph2, isn't it?
NewPenguin, published July 27, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5083 seconds.